{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:02:49Z","timestamp":1789455769551,"version":"build-2803163510"},"reference-count":81,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This systematic review and meta\u2010analysis aimed to evaluate the association between \u03b2\u2010blocker use and neuropsychiatric adverse events, specifically focusing on short\u2010term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search identified studies reporting neuropsychiatric outcomes in patients using \u03b2\u2010blockers, including randomized controlled trials and observational studies. Relative risks (RR) and 95% confidence intervals (CIs) were calculated for outcomes such as dizziness, insomnia, nightmares, drowsiness and delirium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our analysis revealed that \u03b2\u2010blocker use was significantly associated with an increased risk of dizziness (RR 1.72, 95% CI [1.39\u20132.14];\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20091%, 14 studies) compared to placebo. Lipophilic \u03b2\u2010blockers, especially propranolol, showed an even greater risk of dizziness (RR 3.13, 95% CI [1.44\u20136.84];\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%, three studies). Propranolol was also associated with increased insomnia risk compared to placebo (RR 1.13, 95% CI [1.00\u20131.28];\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%, five studies). Our data did not show statistically significant increases in the reports of nightmares and somnolence. Other adverse effects, including drowsiness, sleep disturbances, hallucinations and delirium, were noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest a significant association between \u03b2\u2010blocker use and an increased risk of neuropsychiatric adverse events, particularly insomnia and dizziness with higher risks associated with lipophilic \u03b2\u2010blocker use. Given the ambiguity surrounding dizziness and its classification as a neuropsychiatric effect, our findings are exploratory, and we cannot exclude a potential cardiovascular origin for dizziness. Most studies (75%) were published before the CONSORT statement in 1996, indicating potential reporting limitations and a lack of recent research. Additionally, 60% of studies had a high risk of bias, underscoring the need for more rigorous and contemporary investigations into the neuropsychiatric implications of \u03b2\u2010blocker use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.16361","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:54:50Z","timestamp":1733867690000},"page":"325-337","source":"Crossref","is-referenced-by-count":25,"title":["\u03b2\u2010Blockers and risk of neuropsychiatric disorders: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"91","author":[{"given":"Lujain Ez","family":"Eddin","sequence":"first","affiliation":[{"name":"ICES Western  London ON Canada"},{"name":"Department of Physiology and Pharmacology Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Preyra","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"ICES Western  London ON Canada"},{"name":"Department of Epidemiology &amp; Biostatistics Western University  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Jafari","sequence":"additional","affiliation":[{"name":"ICES Western  London ON Canada"},{"name":"Department of Epidemiology &amp; Biostatistics Western University  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-0699","authenticated-orcid":false,"given":"Mohammad Ali","family":"Omrani","sequence":"additional","affiliation":[{"name":"ICES Western  London ON Canada"},{"name":"Department of Physiology and Pharmacology Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4682-6564","authenticated-orcid":false,"given":"Flory T.","family":"Muanda","sequence":"additional","affiliation":[{"name":"ICES Western  London ON Canada"},{"name":"Department of Physiology and Pharmacology Western University  London Ontario Canada"},{"name":"Department of Epidemiology &amp; Biostatistics Western University  London ON Canada"},{"name":"Lawson Health Research Institute, London Health Sciences Centre  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010197407010\u201000006"},{"key":"e_1_2_9_3_1","unstructured":"Cleveland Clinic.Beta\u2010blockers: Types Uses and Side Effects.https:\/\/my.clevelandclinic.org\/health\/treatments\/22318-beta-blockers. Accessed February 14 2024."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.05.068"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6121.1182"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1015761618314"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2010.04.008"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.accreview.2004.08.097"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57020155"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010199920020\u201000002"},{"key":"e_1_2_9_11_1","unstructured":"Atenolol: Drug information\u2014UpToDate.https:\/\/www.uptodate.com\/contents\/atenolol-drug-information. Accessed October 28 2024."},{"key":"e_1_2_9_12_1","unstructured":"Metoprolol (Product Monograph).https:\/\/pdf.hres.ca\/dpd_pm\/00067786.PDF. Accessed October 28 2024."},{"key":"e_1_2_9_13_1","unstructured":"Propranolol (Product Monograph).https:\/\/pdf.hres.ca\/dpd_pm\/00014382.PDF. Accessed October 28 2024."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.75.1.204"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleepe.2023.100066"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010021\u201001626\u20104"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21f14095"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16590"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(86)90046\u20102"},{"key":"e_1_2_9_20_1","unstructured":"Cochrane Training.Chapter 10: Analysing data and undertaking meta\u2010analyses.https:\/\/training.cochrane.org\/handbook\/current\/chapter-10. Accessed June 18 2024."},{"key":"e_1_2_9_21_1","unstructured":"RyanR Cochrane Consumers and Communication Review Group.Cochrane Consumers and Coomunication Review Group: meta\u2010analysis.2016https:\/\/cccrg.cochrane.org\/sites\/cccrg.cochrane.org\/files\/uploads\/meta-analysis_revised_december_1st_1_2016.pdf. Accessed November 28 2024."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102288\u20107\u20105"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_9_24_1","unstructured":"RevMan.https:\/\/training.cochrane.org\/online\u2010learning\/core\u2010software\/revman. Accessed June 28 2024."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380160072023"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007998309109805"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199220004-00010"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390110039009"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751\u20107176.2010.00341.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002\u20109149(83)90579\u20109"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198700003-00013"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6620.468"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002\u20108703(82)90143\u20100"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.92.6.1499"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010198800366\u201000015"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753944710387629"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1076\u20107460.2004.3624.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605233342101"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006057500300101"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960170509"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002\u20109149(84)90300\u2010X"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001882"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552\u20104604.1995.tb05009.x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468\u20102982.1989.904247.x"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/1.3.295S"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751\u20107176.2009.00119.x"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167\u20105273(92)90238\u2010X"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006058501300207"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/2.11.840"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/1.3.206S"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370020109046"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320370021023"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5967.367"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526\u20104610.1983.hed2301026.x"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000571"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010004\u20100464\u20106"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK\u201012\u2010RG\u2010004"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908142"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1994.11812896"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510060059034"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010198300252\u201000007"},{"issue":"6","key":"e_1_2_9_62_1","first-page":"624","article-title":"Postmarketing comparison of labetalol and propranolol in hypertensive patients","volume":"8","author":"Due DL","journal-title":"Clin Ther"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007998509109613"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00543713"},{"issue":"4","key":"e_1_2_9_65_1","first-page":"185","article-title":"Pindolol, (Visken, LB46). A new treatment for hypertension: report of a multicentric open study","volume":"14","author":"Collins IS","year":"1972","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561896"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8236"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A476"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00543714"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752\u20101947\u20106\u201065"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053\u2010199803000\u201000010"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6655.1048\u2010b"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2012.03.007"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002808401800709"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u201090\u20106\u2010938"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.63.735.57"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.47.6.537"},{"issue":"2","key":"e_1_2_9_78_1","first-page":"29","article-title":"The man who saw things on carvedilol","volume":"44","author":"Aikoye SA","year":"2019","journal-title":"Tokai J Exp Clin Med"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370404900922"},{"issue":"1","key":"e_1_2_9_80_1","first-page":"40","article-title":"Low dose propranolol\u2010induced delirium: 3 cases report and a review of literature","volume":"10","author":"Chen WH","year":"1994","journal-title":"Gaoxiong Yi Xue Ke Xue Za Zhi"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00543711"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.2122"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T02:07:16Z","timestamp":1738030036000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/bcp.16361"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16361","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}